Natalizumab (Tyruko ® & Tysabri® )
AI Summary
UnitedHealthcare has revised their medical benefit drug policy for Natalizumab (Tyruko® & Tysabri®), which are specialty medications used primarily for multiple sclerosis and Crohn's disease treatment. This policy update will take effect July 1, 2026 and may impact prior authorization requirements, coverage criteria, or billing procedures for these high-cost specialty drugs.
Action Required
Before July 1, 2026: Billing team must review the complete policy document at the provided URL to understand specific changes to Natalizumab coverage requirements. Update prior authorization procedures and coverage criteria in billing system for Tyruko® and Tysabri®. Notify providers who prescribe these medications about any new documentation or approval requirements.
Plan Types
Commercial
Specialties
neurology, gastroenterology, rheumatology